Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients

ETP-ALL like patients have poor outcomes and prognosis, and the optimal therapeutic approaches are poorly characterized. The goal of this clinical trial is to evaluate the efficacy and safety of the venetoclax combined with azacitidine, chidamide, vindesine, and dexamethasone regimen in newly diagnosed ETP-ALL like patinets (including ETP-ALL, near ETP-ALL and T-ALL with myeloid mutations) .

NCT Number	NCT07159620
Lead Sponsor	The First Affiliated Hospital of Soochow University
Conditions	Adult T-cell Leukemia/Lymphoma
Enrollment	27 participants
Start Date	2025-09-01
Primary Completion	2028-09-01 (estimated)
Study Completion	2030-09-01 (estimated)
Updated on ClinicalTrials.gov	2025-09-08